DOI QR코드

DOI QR Code

Prognostic Significance of Circulating Tumor Cells and Serum CA15-3 Levels in Metastatic Breast Cancer, Single Center Experience, Preliminary Results

  • Tarhan, Mustafa Oktay (Clinic of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) ;
  • Gonel, Ataman (Department of Biochemistry, Izmir Katip Celebi University Ataturk Training and Research Hospital) ;
  • Kucukzeybek, Yuksel (Clinic of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) ;
  • Erten, Cigdem (Clinic of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) ;
  • Cuhadar, Serap (Department of Biochemistry, Izmir Katip Celebi University Ataturk Training and Research Hospital) ;
  • Yigit, Seyran Ceri (Department of Pathology, Izmir Katip Celebi University Ataturk Training and Research Hospital) ;
  • Atay, Aysenur (Clinic of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) ;
  • Somali, Isil (Clinic of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) ;
  • Dirican, Ahmet (Clinic of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) ;
  • Demir, Lutfiye (Clinic of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital) ;
  • Koseoglu, Mehmet (Department of Biochemistry, Izmir Katip Celebi University Ataturk Training and Research Hospital)
  • Published : 2013.03.30

Abstract

Background: Breast cancer is the second leading cancer causing death in women. Circulating tumor cells are among the prognostic factors while tumor markers are of diagnostic value and can be used for follow-up. The aim of this study was to investigate the correlation between the prognostic significance of the serum CA15-3 levels, number of circulating tumor cells and histopathological tumor factors. Materials and Methods: Thirty patients recently diagnosed with breast cancer were included in the study. Number of circulating tumor cells and serum CA15-3 level were assessed when metastasis was detected and diagnostic value was assessed. Presence of associations with estrogen and progesterone receptors, c-erbB2, Ki-67 proliferation index and histological grade were also evaluated. Results: Median overall survival of the patients with serum CA15-3 levels of >108 ng/dl was 19 months whereas for those with a low serum level it was 62 months. Median overall survival for CTC ${\geq}5$ vs CTC<5 patients was 19 months and 40 months respectively. The difference between the two groups was statistically significant. Conclusions: Prognostic significance of the CTC count and CA15-3 levels in metastatic breast cancer patients was demonstrated.

References

  1. Allard WJ, Matera J, Miller MC, et al (2004). Tumor cells circulate in the peripheral blood of all major carcinomas but not in the healthy subjects or patients with non-malignant diseases. Clin Cancer Res, 10, 6897-904. https://doi.org/10.1158/1078-0432.CCR-04-0378
  2. Andreopoulou E, Hortobagyi GN (2008). Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy. J Clin Oncol, 26, 3660-2. https://doi.org/10.1200/JCO.2008.16.1026
  3. Asworth TR (1869). A case of cancer in which cells similar to those in tumors were seen in the blood after death. Aust Med J, 14, 146-7.
  4. Bidard FC, Hajage D, Bachelot T, et al (2012). Assesment of circulating tumor cells and serum markers for progression free survival prediction in metastatic breast cancer: a prospective observational study. Breast Cancer Res, 14, 29.
  5. Bosl GJ, Motzer RJ (1977). Testicular germ cell cancer. N Engl J Med, 337, 242-51.
  6. Budd GT, Cristofanilli M, Ellis MJ, et al (2006). Circulating tumor cells versus imaging predicting overal survival in metastatic breast cancer. Clin Cancer Res, 12, 6403-9. https://doi.org/10.1158/1078-0432.CCR-05-1769
  7. Colomer R, Ruibal A, Genolla J, et al (1989). Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and non-malignant disease. Breast Cancer Res Treat, 13, 123-33. https://doi.org/10.1007/BF01806524
  8. Colomer R, Ruibal A, Salvador L (1989). Circulating tumor marker levels in advanced breast carcinoma correla te with the extent of melastatic disease. Cancer, 64, 1674-81. https://doi.org/10.1002/1097-0142(19891015)64:8<1674::AID-CNCR2820640820>3.0.CO;2-V
  9. Consoli F, Grisanti S, Amorosso V, et al (2011). Circulating tumor cells as predictors of prognosis in metastatic breast cancer: clinical application outside a clinical trial. Tumori, 97, 7377-742.
  10. Cristofanilli M, Broglio KR, Guarneri V, et al (2007). Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin Breast Cancer, 6, 471-9.
  11. Cristofanilli M, Budd GT, Ellis MJ, et al (2004). Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Eng J Med, 351,781-91. https://doi.org/10.1056/NEJMoa040766
  12. Cristofanilli M, Hayes DF, Budd GT, et al (2005). Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol, 23, 1420-30. https://doi.org/10.1200/JCO.2005.08.140
  13. Dawood S, Broglio KR, Valero V, et al (2008). Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? Cancer, 113, 2422-30. https://doi.org/10.1002/cncr.23852
  14. De Giorgi U, Valero V, Rohren E, et al (2009). Circulating tuoor cells and (18F) fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol, 27, 3303-11. https://doi.org/10.1200/JCO.2008.19.4423
  15. De La Lande B, Hacene K, Floiras J-L, et al (2002). Prognostic value of CA 15-3 kinetics for metastatic breast cancer. Int J Biol Markers, 17, 231-8.
  16. Duffy MJ (2001). Carcinoembriyonik antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem, 47, 624-30.
  17. Fehm T, Muller V, Alix Panabieres C, et al (2008). Micrometastatic spread and breast cancer detection and molecular characterization and clinical relevance. Breast Cancer Res, 10, 1.
  18. Fisher Pm, Hancock BW (1997). Gestational trophoblastic disease and their treatment. Cancer Treat Rev, 23, 1-16. https://doi.org/10.1016/S0305-7372(97)90017-7
  19. Giuliano M, Giordano A, Jackson S, et al (2011). Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first line systemic treatment. Breast Cancer Res, 13, 67. https://doi.org/10.1186/bcr2907
  20. Harris L, Fritsche H, Mennel R, et al (2007). American Society of Clinical Oncology 2007 update of recommendations fort he use of tumor markers in breast cancer. J Clin Oncol, 25, 5287-312. https://doi.org/10.1200/JCO.2007.14.2364
  21. Hayes DF, Cristofanilli M, Budd GT (2006). Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression free and overal survival. Clin Cancer Res, 12, 4218-24. https://doi.org/10.1158/1078-0432.CCR-05-2821
  22. Jacob K, Sollier C, Jabado N (2007). Circulating tumor cells: detection, molecular profiling and future prospects. Expert Rev Proteomics, 4, 741-56. https://doi.org/10.1586/14789450.4.6.741
  23. Kallioniemi O, Oksa H, Aaran R, et al (1988). Serum CA 15 - 3 assay in the diagnosis and follow up of breast cancer. Br J Cancer, 58, 213-5. https://doi.org/10.1038/bjc.1988.196
  24. Lang JE, Mosalpuria K, Cristofanilli M, et al (2009). HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancre. Breast Cancer Res Treat, 113, 501-7. https://doi.org/10.1007/s10549-008-9951-2
  25. Parker C (2004). Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol, 5, 101-6. https://doi.org/10.1016/S1470-2045(04)01384-1
  26. Pierga J-Y, Hajage D, Bachelot T, et al (2012). High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Annals of Oncol, 23, 618-24. https://doi.org/10.1093/annonc/mdr263
  27. Rack BK, Schindlbeck C, Schneeweiss A, et al (2008). Prognostic relevance of circulating tumor cells in peripheral blood of breast cancer patients before and after adjuvant chemotherapy: the german success trial. J Clin Oncol, 26, 7. https://doi.org/10.1200/JCO.2008.19.6451
  28. Ruibal A, Colomer R, Genolla J (1987). Prognostic value of CA 15-3 serum levels in patients having breast cancer. Horm Metab, 1,11-5.
  29. Rustin GJS (2003). Use of CA125 to ases response to new agents in ovarian cancer trials. J Clin Oncol, 21, 187-93. https://doi.org/10.1200/JCO.2003.01.223
  30. Safi F, Kohler I, Rottinger E, et al (1989). Comparison of CA 15 - 3 and CEA in diagnosis and monitoring of breast cancer. Int J Biol Markers, 4, 207-14.
  31. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29. https://doi.org/10.3322/caac.20138
  32. Tampellini M, Berutti A, Gerbino A, et al (1997). Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. Br J Cancer, 75, 698-702. https://doi.org/10.1038/bjc.1997.124
  33. Tewes M, Aktas B, Welt A, et al (2009). Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat, 115, 581-90. https://doi.org/10.1007/s10549-008-0143-x
  34. Tokudome N, Ito Y, Takahashi S, et al (2011). Detection of circulating tumor cells in peripheral blood of heavily treated metastatic breast cancer patients. Breast Cancer, 18, 195-202. https://doi.org/10.1007/s12282-011-0259-4

Cited by

  1. Expression and Significance of ER, PR, VEGF, CA15-3, CA125 and CEA in Judging the Prognosis of Breast Cancer vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3937
  2. Prognostic Role of Circulating Tumor Cells in Patients with Pancreatic Cancer: a Meta-analysis vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6015
  3. Circulating Tumor Cells are Associated with Bone Metastasis of Lung Cancer vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6369
  4. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α Expression in Invasive Ductal Breast Cancer Patients and Correlations with Prognosis vol.16, pp.2, 2015, https://doi.org/10.7314/APJCP.2015.16.2.823
  5. Diagnostic Yield of Primary Circulating Tumor Cells in Women Suspected of Breast Cancer: the BEST (Breast Early Screening Test) Study vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.1929
  6. Usefulness of Salivary and Serum Auto-antibodies Against Tumor Biomarkers HER2 and MUC1 in Breast Cancer Screening vol.17, pp.1, 2016, https://doi.org/10.7314/APJCP.2016.17.1.335
  7. Clinical significance of serum CA15-3 as a prognostic parameter during follow-up periods in patients with breast cancer vol.90, pp.2, 2016, https://doi.org/10.4174/astr.2016.90.2.57
  8. Plasma ALU-247, ALU-115, and cfDNA Integrity as Diagnostic and Prognostic Biomarkers for Breast Cancer pp.1559-0291, 2018, https://doi.org/10.1007/s12010-018-2858-4